Morgan Stanley Cuts Price Target on Disc Medicine to $40 From $75, Says Bitopertin Trial's Missed Secondary Endpoint Increases Uncertainty on Regulatory Path; Equalweight Kept
Morgan Stanley Cuts Price Target on Disc Medicine to $40 From $75, Says Bitopertin Trial's Missed Secondary Endpoint Increases Uncertainty on Regulatory Path; Equalweight Kept
摩根士丹利表示，Bitopertin试验未达到次要终点增加了监管路径的不确定性，将Disc药物的目标股价从75美元下调至40美元；保持同等权重
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册